Your browser doesn't support javascript.
loading
Venetoclax plus hypomethylating agents versus intensive chemotherapy for hematological relapse of myeloid malignancies after allo-HSCT.
Chen, Zhangjie; Zhen, Sisi; Zhang, Tingting; Shen, Yuyan; Pang, Aiming; Yang, Donglin; Zhang, Rongli; Ma, Qiaoling; He, Yi; Wei, Jialin; Zhai, Weihua; Chen, Xin; Jiang, Erlie; Han, Mingzhe; Feng, Sizhou.
Affiliation
  • Chen Z; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
  • Zhen S; Tianjin Institutes of Health Science, Tianjin, China.
  • Zhang T; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
  • Shen Y; Tianjin Institutes of Health Science, Tianjin, China.
  • Pang A; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
  • Yang D; Tianjin Institutes of Health Science, Tianjin, China.
  • Zhang R; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
  • Ma Q; Tianjin Institutes of Health Science, Tianjin, China.
  • He Y; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
  • Wei J; Tianjin Institutes of Health Science, Tianjin, China.
  • Zhai W; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
  • Chen X; Tianjin Institutes of Health Science, Tianjin, China.
  • Jiang E; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
  • Han M; Tianjin Institutes of Health Science, Tianjin, China.
  • Feng S; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
Front Oncol ; 13: 1137175, 2023.
Article de En | MEDLINE | ID: mdl-37035180
Mots clés
Texte intégral
Ajouter à My VHL
Imprimer
XML
PubMed Links
Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Langue: En Journal: Front Oncol Année: 2023 Type de document: Article Pays d'affiliation: Chine Pays de publication: Suisse
Texte intégral
Ajouter à My VHL
Imprimer
XML
PubMed Links
Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Langue: En Journal: Front Oncol Année: 2023 Type de document: Article Pays d'affiliation: Chine Pays de publication: Suisse